TAS-102: 9 Real Stories

9 stories match TAS-102. 8 of them mention targeted therapy.

Sydney, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Sydney Stoner: Stage IIIB to Stage IV colon cancer with liver and lung involvement

Patient Info: Sydney Stoner, Female, Under 40 | Stage IV

Metastatic Site: Liver; lungs

Progressed from Stage IIIB colon cancer to Stage IV disease involving the liver and lungs; treated with surgery/ileostomy/reversal, FOLFOX/FOLFIRI, lung radiation, liver ablation/resection, capecitabine, and ongoing Lonsurf + Avastin.

Fight Colorectal Cancer
OutcomeSetback / Progression
Sydney, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Sydney's Patient Story

Patient Info: Sydney, Female | Stage IV

Metastatic Site: Liver; lungs

Sydney was living with Stage IV colorectal cancer involving the liver and lungs. After multiple lines of treatment, she had a new liver spot and was back on lower-dose FOLFIRI every other Tuesday with a 46-hour pump.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Stage IV gastric cancer with benign breast hemangioma during ramucirumab therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Gastric cancer: HER2 negative, PD-L1 TPS >=5%

Metastatic Site: peritoneum; preaortic lymph nodes; omentum

After initial response to FOLFOX/nivolumab and temporary benefit from paclitaxel/ramucirumab and FOLFIRI, the gastric cancer progressed to massive ascites. Trifluridine/tipiracil was attempted, but she died from rapid disease progression.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Kidney complication after switching colorectal cancer chemotherapy regimens

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver

The cancer had worsening liver metastases when FTD/TPI began. After treatment was stopped, steroid therapy resolved edema within 1 month and proteinuria returned to baseline 2.5 months after admission; the later cancer course was not established.

PubMed Central
OutcomeIn Treatment
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV transverse colon cancer with NTRK fusion: entrectinib response followed by fatal PTTM

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: RAS/BRAF wild type, low TMB. CEA and CA19-9 were elevated before entrectinib and fell with response.

Metastatic Site: peritoneum, greater omentum, pleura,…

He died 7 weeks after hospitalization from pulmonary tumor thrombotic microangiopathy causing severe pulmonary hypertension and right-heart failure, despite biochemical and ascites response to entrectinib.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Severe immune thrombocytopenia during treatment for metastatic colon cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: KRAS-mutated; microsatellite stable; BRAF-wild type.

Metastatic Site: bilateral ovaries; pelvis; peritoneum; mesenteric…

After multiple metastatic recurrences and treatment changes, she died from progressive colon cancer; oxaliplatin had been permanently stopped after antibody-confirmed immune thrombocytopenia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Bilateral adrenal bleeding during bevacizumab treatment for metastatic colon cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: RAS-mutant; BRAF-wild type; microsatellite stable.

Metastatic Site: peritoneum; liver; lung

Despite multiple systemic and local treatments, his metastatic colon cancer progressed in the liver and peritoneum, and he died from disease progression in November 2018.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Gastric AdenocarcinomaGastric Cancer

Clival skull-base metastasis during treatment for Stage IV gastric cancer

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: HER2-negative

Metastatic Site: peritoneum, cervical lymph nodes, pelvic bone, lungs,…

At publication he was alive on fourth-line treatment, with no disease progression for 6 months after the clival metastasis was treated and with sustained improvement in his cranial-nerve symptoms.

PubMed Central
OutcomeStable Disease